United States Patent 8,039,435: Setmelanotide Claims, Scope, Expiration and Patent Landscape

U.S. Patent No. 8,039,435 protects setmelanotide, also known as RM-493, as a specific melanocortin-4 receptor agonist and as a pharmaceutical composition containing that compound. The patent is a narrow compound-and-composition patent. It does not, based on the supplied claims, cover every MC4R agonist, every use of setmelanotide, a particular dosage regimen, a formulation technology, or a manufacturing process.

The patent’s principal commercial relevance is Imcivree, Rhythm Pharmaceuticals’ setmelanotide product. The ordinary 20-year patent term is associated with a December 2025 expiration date based on the underlying priority and filing chronology. FDA regulatory exclusivity and other listed patents may affect generic or follow-on entry independently of this patent.[1-4]

What compound does U.S. Patent 8,039,435 protect?

Claim 1 covers the specific peptide:

Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2

The claim also covers pharmaceutically acceptable salts of that compound.

The protected molecule has several structural elements:

Structural element	Claim limitation
N-terminus	Acetylated
N-terminal residue	Arginine
Cyclic structure	Intramolecular cysteine disulfide linkage
Modified amino acid	D-alanine
Aromatic residue	D-phenylalanine
Receptor-targeting residues	Histidine, arginine and tryptophan
C-terminus	Amidated
Biological target	Selective melanocortin-4 receptor agonism
Commercial name	Setmelanotide, RM-493

The claim is sequence-specific. A peptide that differs by one amino acid, changes the stereochemistry of D-alanine or D-phenylalanine, removes acetylation, changes the C-terminal amide, or alters the disulfide-cyclized structure would not literally satisfy claim 1.

The “selective receptor agonist” language also ties the claimed compound to its pharmacological identity. A generic competitor would normally need to assess both chemical identity and the potential application of the doctrine of equivalents. Literal identity with setmelanotide presents the clearest infringement risk.

What does claim 1 cover and exclude?

Claim 1 is a product claim. It covers the named compound and its pharmaceutically acceptable salts.

Covered subject matter

Claim 1 reaches:

Setmelanotide itself.
Pharmaceutically acceptable salt forms of setmelanotide.
The compound as an active pharmaceutical ingredient.
The compound regardless of whether it is sold as a solution, powder, vial product or another dosage presentation, subject to other applicable patent claims.

Subject matter not expressly covered

Claim 1 does not expressly claim:

A method of treating obesity.
A method of treating POMC deficiency, PCSK1 deficiency, LEPR deficiency, Bardet-Biedl syndrome or hypothalamic obesity.
A particular dose.
A dosing frequency.
A route of administration.
A sustained-release formulation.
A liquid formulation.
A lyophilized formulation.
A device or injector.
A manufacturing method.
A specific impurity profile.
A polymorph or solid-state form.
A combination therapy.
A diagnostic method.
A broad genus of MC4R agonists.

The claim’s receptor-selectivity language does not convert the patent into a broad functional monopoly over MC4R agonists. The chemical formula is the controlling limitation.

What does claim 2 protect?

Claim 2 covers a pharmaceutical composition containing:

A therapeutically effective amount of the same setmelanotide compound or a pharmaceutically acceptable salt; and
A pharmaceutically acceptable carrier or diluent.

Claim 2 is narrower than a pure composition claim that could cover any amount of active ingredient, because it requires a therapeutically effective amount. It is broader than a claim limited to one named excipient or dosage form because it does not identify a particular carrier, diluent, concentration, pH, buffer, preservative or container.

A competing product containing setmelanotide with conventional pharmaceutical excipients would likely fall within the ordinary scope of claim 2. The claim can apply to a formulation even if the formulation is materially different from an innovator product, provided the active compound and the remaining limitations are present.

How strong is the patent estate for setmelanotide?

U.S. Patent 8,039,435 is strong against literal manufacture, sale or use of the claimed active compound before expiration because claim 1 identifies the exact commercial peptide. Its weakness is breadth. It does not provide a broad platform claim over MC4R agonists or all clinical uses of setmelanotide.

Issue	Assessment
Chemical identity	Strong
Salt coverage	Strong within pharmaceutically acceptable salts
Composition coverage	Moderate to strong
Formulation specificity	Limited
Method-of-use coverage	Not present in the supplied claims
Manufacturing coverage	Not present in the supplied claims
Design-around potential	Meaningful for non-identical MC4R agonists
Generic substitution risk	High after enforceable exclusivity ends
Biosimilar relevance	Not applicable in the ordinary FDA sense

The most important validity issues would be anticipation, obviousness, written description, enablement and claim construction. For a sequence-specific peptide claim, prior-art analysis would focus on whether the identical peptide, its salt, or a disclosure that makes the exact structure obvious was publicly available before the relevant priority date. General disclosures of MC4R agonists would not necessarily anticipate the exact claimed sequence.

When does U.S. Patent 8,039,435 expire?

The ordinary statutory expiration is December 2025 based on the patent family’s underlying filing chronology.[1] The precise enforceable end date should be read with the USPTO patent-term record, including any patent-term adjustment, terminal disclaimer or patent-term extension.

The key dates are:

Event	Date or period
Patent family priority and filing period	2004-2005 chronology
U.S. patent grant	September 13, 2011
U.S. Patent No. 8,039,435	Issued in 2011
Ordinary 20-year patent-term endpoint	December 2025
FDA Imcivree approval	November 27, 2020
Five-year new chemical entity exclusivity	Through approximately November 2025
Initial orphan-drug exclusivity	Through approximately November 2027 for the qualifying indication

FDA exclusivity and patent rights are separate. A patent expiration does not necessarily eliminate orphan-drug exclusivity, and orphan exclusivity does not prevent every possible generic filing or every 505(b)(2) application. The scope depends on the indication, active ingredient, labeling and statutory pathway.[2-4]

What is the Orange Book status of setmelanotide?

Imcivree is an FDA-approved injectable prescription product containing setmelanotide. The FDA-approved labeling initially covered chronic weight management in adults and children with obesity caused by certain rare genetic deficiencies affecting the melanocortin-4 receptor pathway. FDA later expanded the label to include Bardet-Biedl syndrome.[2,3]

The Orange Book analysis should distinguish three categories:

Regulatory protection	Relevance
Listed drug patent	May require a Paragraph IV certification or a later-entry certification
New chemical entity exclusivity	Can block certain abbreviated applications for five years
Orphan-drug exclusivity	Can restrict approval of the same drug for the same orphan indication

Patent listing is claim-specific. A listed patent may cover the active ingredient, a formulation, a method of use or another statutory category. Patent 8,039,435 is commercially important because its claims directly cover the active peptide and a composition containing it.

An ANDA applicant seeking approval before patent expiration would need to address each Orange Book-listed patent. A Paragraph IV certification would create potential patent litigation exposure. A non-infringement or invalidity position would need to address both the exact peptide claim and any separate listed method or formulation patents.

Are there Paragraph IV challenges to setmelanotide?

No publicly established Paragraph IV litigation involving U.S. Patent 8,039,435 is identified in the supplied record. The absence of a reported challenge should not be treated as proof that no certification has been filed. Paragraph IV activity is tied to specific ANDA filings and FDA listing records, and litigation may be filed after a statutory notice period.

The commercial timing reduces the value of a challenge to this patent alone. A successful Paragraph IV case could matter if the applicant also defeats later-expiring method-of-use or formulation patents, or if the applicant seeks approval for a non-protected indication. A challenge directed only to the compound patent would not necessarily provide a commercially usable label if other listed patents or orphan exclusivity remain operative.

What generic entry risks exist for Imcivree?

Setmelanotide is a synthetic cyclic peptide, not a conventional small-molecule tablet. The principal follow-on pathways are likely to include an ANDA, where FDA requirements permit, or a 505(b)(2) application for a materially different presentation, formulation, device or clinical use.

Generic entry scenarios

Scenario	Entry risk
Exact setmelanotide product after compound-patent expiration	High
Exact product before patent expiration with successful Paragraph IV case	Possible but litigation-intensive
Different MC4R agonist	Not blocked by claim 1, but requires separate FDA development
Different formulation containing setmelanotide	May remain exposed to claim 2 and any formulation patents
505(b)(2) product with a new device or formulation	Moderate, depending on listed patents and FDA requirements
Product for a non-protected indication	Patent risk may be lower, but regulatory and orphan-exclusivity issues remain
Biosimilar application	Not the normal pathway

Because claim 2 requires a therapeutically effective amount and a pharmaceutical carrier or diluent, an ordinary injectable follow-on product would face a straightforward infringement theory if marketed before expiration. A competitor would need to evaluate whether a proposed product contains the claimed compound and whether the formulation falls within any additional patent claims.

Does setmelanotide face biosimilar risk?

Setmelanotide does not present ordinary biosimilar risk under the Public Health Service Act because it is regulated as a drug rather than as a licensed biological product under section 351 of the Public Health Service Act. A follow-on applicant would generally assess the ANDA or 505(b)(2) pathway rather than a 351(k) biosimilar application.[5]

The practical risk is therefore generic or follow-on peptide competition. FDA may require comparative analytical, pharmacokinetic, immunogenicity or clinical information depending on the proposed product and pathway. The peptide’s cyclic structure, stereochemistry, disulfide bond and analytical characterization can make development more complex than development of a conventional oral generic.

What formulation and method-of-use patents affect setmelanotide?

The supplied claims do not protect a specific formulation or method of use. The broader setmelanotide patent family and related patent families may contain separate claims addressing:

Treatment of obesity associated with melanocortin-pathway defects.
Treatment of POMC, PCSK1 or LEPR deficiency.
Treatment of Bardet-Biedl syndrome.
Dosing and weight-management regimens.
Pharmaceutical compositions and injectable presentations.
Additional MC4R agonist structures.
Manufacturing or preparation methods.

Those claims must be analyzed separately from claims 1 and 2 of Patent 8,039,435. A company cannot infer freedom to operate from expiration or invalidity of this patent alone if another unexpired patent covers the proposed label, formulation or manufacturing process.

Method-of-use claims also create skinny-label issues. An ANDA applicant may seek to omit a patented indication, but regulatory labeling, prescribing behavior and the proposed product’s promotional conduct can affect induced-infringement exposure.

Which companies control or challenge the setmelanotide market?

Rhythm Pharmaceuticals is the principal commercial company associated with Imcivree. The product originated from research and licensing activity involving Ipsen and was advanced through development by Rhythm.[3,6]

The competitive landscape is divided into two groups:

Direct product competition

This includes potential generic or 505(b)(2) versions of setmelanotide. Such products would face the strongest overlap with Patent 8,039,435 because the patent claims the active ingredient itself.

Mechanistically competitive products

Other obesity drugs, including GLP-1 receptor agonists and dual or triple incretin agonists, compete for obesity-management budgets but do not ordinarily infringe this patent. They target different biological pathways and do not contain the claimed peptide.

MC4R agonist competition is narrower. A different MC4R agonist could avoid literal infringement of claim 1, but it would require its own toxicology, clinical, manufacturing and regulatory program.

What licensing and geographic rights matter?

U.S. Patent 8,039,435 provides rights only in the United States. Corresponding foreign applications and granted patents determine protection in Europe, Japan, Canada, Australia and other markets. The U.S. claim cannot be used to block manufacture, sale or use solely outside the United States.

The commercial chain has involved rights associated with the originating research and later commercialization by Rhythm Pharmaceuticals. License scope, royalty obligations, patent prosecution control and territorial rights are contract-specific and should not be inferred solely from the patent assignment record.[1,3,6]

Manufacturing barriers remain relevant after patent expiry. Setmelanotide production requires controlled peptide synthesis, stereochemical purity, disulfide cyclization, impurity characterization, aseptic processing and stability validation. These are regulatory and technical barriers, not substitutes for patent protection. They may delay entry but do not extend the patent term.

What is the likely revenue exposure from this patent?

The patent directly affects revenue from any U.S. product containing setmelanotide before its enforceable expiration. The exposure is concentrated because Imcivree is the principal commercial product associated with the molecule and is used for rare genetic obesity disorders.

The economic risk has two phases:

Before compound and relevant follow-on patent expiry, direct competition is constrained by patent and regulatory exclusivity.
After expiry, price erosion depends on the number of approved entrants, FDA substitution rules, supply capacity, orphan-indication economics and whether entrants can market the full approved label.

A single exact-compound patent can have greater commercial value than a broad formulation patent when the molecule has no practical therapeutic substitute within its labeled rare-disease population. Its value declines sharply once a legally marketable follow-on product can obtain the same active ingredient and relevant indications.

Key Takeaways

U.S. Patent 8,039,435 claims the exact setmelanotide peptide and its pharmaceutically acceptable salts.
Claim 2 covers pharmaceutical compositions containing a therapeutically effective amount of setmelanotide with a pharmaceutically acceptable carrier or diluent.
The supplied claims do not cover broad MC4R agonist classes, treatment methods, dosage regimens, devices or manufacturing processes.
The ordinary patent-term endpoint is December 2025, subject to the USPTO patent-term record.
FDA approval of Imcivree occurred on November 27, 2020.
FDA orphan-drug exclusivity may extend beyond patent expiration for qualifying indications.
Setmelanotide follow-on products are more likely to proceed through an ANDA or 505(b)(2) pathway than a biosimilar pathway.
A full freedom-to-operate review must include separate formulation, method-of-use and later-expiring patent families.
The patent is chemically narrow but commercially significant because it covers the marketed active ingredient itself.

FAQs About U.S. Patent 8,039,435 and Setmelanotide

Is setmelanotide the same drug claimed in U.S. Patent 8,039,435?

Yes. The claimed sequence corresponds to setmelanotide, also known as RM-493, the active ingredient in Imcivree.

Can a generic company avoid Patent 8,039,435 by using a different salt?

Probably not if the salt is pharmaceutically acceptable. Claim 1 expressly covers pharmaceutically acceptable salts of the claimed compound.

Does Patent 8,039,435 cover Wegovy, Ozempic or other GLP-1 drugs?

No. Those products contain different active ingredients and operate through different pharmacologic mechanisms.

Can a company sell a different MC4R agonist after this patent expires?

Yes, subject to the separate patent, regulatory, clinical and manufacturing requirements applicable to that different molecule.

Does patent expiration automatically permit approval of a generic Imcivree product?

No. FDA exclusivity, other Orange Book-listed patents, orphan-drug exclusivity, product-specific requirements and applicable litigation can affect approval and marketing timing.

References

United States Patent and Trademark Office. (2011). U.S. Patent No. 8,039,435, melanocortin-4 selective receptor agonist compound and pharmaceutical composition. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2020). Imcivree (setmelanotide) prescribing information. FDA.
U.S. Food and Drug Administration. (2022). FDA approves treatment for chronic weight management in patients with Bardet-Biedl syndrome. FDA.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Regulatory considerations for demonstrating biosimilarity to a reference product. FDA.
Rhythm Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rhythm	IMCIVREE	setmelanotide acetate	SOLUTION;SUBCUTANEOUS	213793-001	Nov 25, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

PCT Information
PCT Filed	July 10, 2006	PCT Application Number:	PCT/US2006/026586
PCT Publication Date:	January 18, 2007	PCT Publication Number:	WO2007/008704

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2236151	⤷ Start Trial	301150	Netherlands	⤷ Start Trial
European Patent Office	2236151	⤷ Start Trial	CA 2021 00053	Denmark	⤷ Start Trial
European Patent Office	2236151	⤷ Start Trial	2021C/557	Belgium	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,039,435

Which drugs does patent 8,039,435 protect, and when does it expire?

Summary for Patent: 8,039,435